Cancer heterogeneity and signaling network-based drug target

References

• 1  Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature486(7403),353–360 (2012).
  Medline CASGoogle Scholar
• 2  Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature486(7403),405–409 (2012).
  Medline CASGoogle Scholar
• 3  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407),330–337 (2012).
  Medline CASGoogle Scholar
• 4  ENCODE Project Consortium, Dunham I, Kundaje A et al. An integrated encyclopedia of DNA elements in the human genome. Nature489(7414),57–74 (2012).
  Medline CASGoogle Scholar
• 5  Stamatoyannopoulos JA. What does our genome encode? Genome Res.22(9),1602–1611 (2012).
  Medline CASGoogle Scholar
• 6  Maurano MT, Humbert R, Rynes E et al. Systematic localization of common disease-associated variation in regulatory DNA. Science337(6099),1190–1195 (2012).
  Medline CASGoogle Scholar
• 7  Gerstein MB, Kundaje A, Hariharan M et al. Architecture of the human regulatory network derived from ENCODE data. Nature489(7414),91–100 (2012).
  Medline CASGoogle Scholar
• 8  He Y, Fang J, Taatjes DJ, Nogales E. Structural visualization of key steps in human transcription initiation. Nature495(7442),481–486 (2013).
  Medline CASGoogle Scholar
• 9  Chung K, Wallace J, Kim SY et al. Structural and molecular interrogation of intact biological systems. Nature497(7449),332–337 (2013).
  Medline CASGoogle Scholar
• 10  Pelechano V, Wei W, Steinmetz LM. Extensive transcriptional heterogeneity revealed by isoform profiling. Nature497(7447),127–131 (2013).
  Medline CASGoogle Scholar
• 11  Pugh BF. Molecular biology: the ends justify the means. Nature497(7447),48–49 (2013).
  Medline CASGoogle Scholar
• 12  Roukos DH, Ziogas DE, Baltogiannis GG et al. Novel next-generation sequencing and networks-based therapeutic targets: realistic more effective drug design and discovery. Curr. Pharm. Des. doi:10.2174/13816128113199990385 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 13  Erler JT, Linding R. Network medicine strikes a blow against breast cancer. Cell149(4),731–733 (2012).
  Medline CASGoogle Scholar
• 14  Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A et al. Basal/HER2 breast carcinomas integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle12(2),225–245 (2013).
  Medline CASGoogle Scholar
• 15  Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med.368,2385–2394 (2013)
  Medline CASGoogle Scholar
• 16  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5),646–674 (2011).
  Medline CASGoogle Scholar
• 17  Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol.8,565 (2012).
  MedlineGoogle Scholar
• 18  Zhang QC, Petrey D, Garzón JI, Deng L, Honig B. PrePPI: a structure-informed database of protein-protein interactions. Nucleic Acids Res.41(D1),D828–D833 (2013).
  Medline CASGoogle Scholar
• 19  Cheng TM, Gulati S, Agius R, Bates PA. Understanding cancer mechanisms through network dynamics. Brief Funct.Genomics11(6),543–560 (2012).
  Medline CASGoogle Scholar
• 20  Depry C, Mehta S, Zhang J. Multiplexed visualization of dynamic signaling networks using genetically encoded fluorescent protein-based biosensors. Pflugers Arch.465(3),373–381 (2013).
  Medline CASGoogle Scholar
• 101  US FDA. Cetuximab in Combination with Folfiri/Therascreen. www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm310933.htm
  Google Scholar